Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander D. Voropaev has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The feasibility and specific aspects of hematopoietic stem cell transplantation in children with pre-transplant invasive mucormycosis

    by Galina G. Solopova, Солопова Галина Геннадьевна, L. N. Shelikhova, Шелихова Л. Н., Zh. V. Markova, Маркова Ж. В., A. P. Shcherbakov, Щербаков А. П., A. D. Voropaev, Воропаев А. Д., et al.

    Introduction. The rising incidence of mucormycosis among patients with hematologic and oncologic conditions has made it crucial to develop principles for the treatment of infectious complications as well as to assess the feasibility of allogeneic hematopoietic stem cell transplantation (HSCT) in this population. Aim: to analyze the specific aspects and safety of HSCT in children with mucormycosis. Materials and methods. This retrospective-prospective single-center study, conducted from 1 January 2013 to 31 March 2026 at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation, included HSCT recipients with a pre-transplant diagnosis of mucormycosis. The diagnostic work-up included computed tomography, magnetic resonance imaging, ultrasound, endoscopy, bronchoalveolar lavage, and biopsy of various organs and tissues depending on the site of involvement. From these specimens, slides were prepared in clearing solution supplemented with calcofluor white, a fluorescent agent. The slides were then examined under a fluorescence microscope using short-wavelength excitation at 400× magnification. Results. We analyzed treatment outcomes in 13 patients (median age: 11.7 years), 77% of whom had hematologic malignancies. At mucormycosis onset, pulmonary involvement was observed in 62% of the patients, paranasal sinus involvement in 54%; liver, spleen, and central nervous system involvement in 8%, and disseminated disease in 31%. Etiologic confirmation (77%) revealed Lichtheimia corymbifera (n = 2), Rhizomucor pusillus (n = 2), Rhizopus oryzae (n = 2), Rhizopus microsporus (n = 1), Mucor indicus (n = 1), and Mucor spp. (n = 2). All the patients received targeted antifungal therapy (amphotericin B, posaconazole, isavuconazole), with combination treatment used in 77% of cases. Surgical treatment was performed in 92% of the cases. Notably, radical resection significantly reduced the need for repeat surgeries (p = 0.02). Allogeneic HSCT was mostly performed using ex vivo αβ T-cell depletion (n = 11). At the time of transplantation, active infection was observed in 5 patients, partial response in 5 and complete response in 3. The median time to engraftment was 12 (10–35) days. Glucocorticoids for graft-versus-host disease were required in 3 patients. Mucormycosis was cured in 100% of cases. The median time to complete response was 82 days with early partial response (8 weeks) and 179 days with late response (p = 0.002). Infection status at HSCT did not affect the time to mucormycosis resolution. The overall survival was 59%, without any mucormycosis-associated deaths. Conclusion. The use of modern HSCT technologies (such as αβ T-cell depletion) in combination with aggressive antifungal treatment enables successful transplantation even in children with active mucormycosis.

  • Open Access

    Fusariosis in immunocompromised pediatric patients: results of a single-center study

    by Galina G. Solopova, Nadezhda V. Suvorova, Anastasia O. Vereshchagina, Zhanna V. Markova, Aleksandr D. Voropaev, O. S. Kozhushnaya, A. V. Satsuk, Galina A. Novichkova

    Over the past two decades, the incidence of rare invasive mycoses, including fusariosis, has increased. Fusariosis remains diagnostically challenging and is associated with high mortality. Here, we present the results of a retrospective-prospective single-center study conducted between 01.01.2013 and 01.11.2025 at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The study aimed to evaluate the clinical characteristics, diagnostic performance, and treatment outcomes of immunocompromised children with fusariosis. It included 16 patients (10 males and 6 females), the median age was 11.5 years (range 2.5–16.0). Hematological malignancies were present in 70% of the cases; primary immunodeficiency, aplastic anemia, osteosarcoma, and systemic lupus erythematosus were less common. Fusariosis developed after chemotherapy (n = 9), hematopoietic stem cell transplantation (n = 4), or immunosuppressive therapy (n = 3). The major risk factors included severe neutropenia and corticosteroid use (87.5%). Disseminated disease occurred in 50% of the patients, localized fusariosis was diagnosed in 40% of the patients, and isolated fungemia was reported in one case. The most frequently affected sites were skin/soft tissues (50%), paranasal sinuses (50%), and lungs (43.75%). Parenchymal organs, bones and eyes were involved less often. The main pathogens were Fusarium solani (n = 6) and Fusarium proliferatum (n = 5), followed by Fusarium oxysporum, Fusarium verticilioides, and Fusarium petroliphilum. Seven patients developed invasive fungal co-infections with Aspergillus flavus (n = 4), Rhizopus spp. (n = 1), Scedosporium aurantiacum (n = 1) and Candida glabrata (n = 1) which was associated with increased mortality. First-line therapy included lipid formulations of amphotericin B (81%) and voriconazole (56%); combination therapy was used in 62.5% of the cases. Fourteen patients achieved a rapid partial response (the median time to response was 21 days), which correlated with favorable outcomes: all these patients were cured and had significantly higher overall survival. In the entire cohort, the 6-week survival was 81%, the overall survival was 69%. The study demonstrated the effectiveness of timely diagnosis and specific therapy for invasive fusariosis in the most vulnerable category of immunocompromised children.

  • Open Access

    Modified Hevein-like Peptide from Amaranthus caudatus as a Promising Agent Against Pathogenic Candida Species

    by Ekaterina I. Finkina, Anastasia A. Gerasimova, Olga V. Shevchenko, Ivan V. Bogdanov, Andrey A. Tagaev, Alexander D. Voropaev, Tatiana V. Ovchinnikova

    Background/Objectives: Currently, infections caused by fungi of the Candida genus remain a significant global health concern. The rising incidence of mycoses, coupled with the rapid emergence of fungal resistance, highlights the urgent need to search for new antifungal agents. Here, we obtained the recombinant hevein-like peptide from Amaranthus caudatus with two amino acid substitutions (F18W in the chitin-binding motif and M13A preventing the peptide from cleavage with cyanogen bromide during its biotechnological production). Methods: Antifungal potential of the modified hevein-like peptide, designated as mAc-AMP2, against susceptible and resistant strains of Candida albicans and non-albicans Candida species was studied. Results: We showed that mAc-AMP2 possessed anticandidal activities against all strains tested at nanomolar peptide concentrations. The presence of salts or serum affected the action of the peptide but its antifungal activity remained quite high. mAc-AMP2 exhibited anti-adherent properties and inhibited the formation of fungal biofilms. Using RP-HPLC, we demonstrated that degradation of the peptide in the presence of serum occurred rather slowly. mAc-AMP2 did not exhibit hemolytic and cytotoxic activities against the Caco-2 cell monolayer and peripheral blood mononuclear cells. Using flow cytometry, we demonstrated that the peptide at its high concentrations increased fungal membrane permeability. In resistance induction experiments, sensitivity of C. albicans toward mAc-AMP2 decreased over time, but restored after the peptide elimination. Conclusions: Taking into account all the data obtained, we suggest that the modified hevein-like peptide is a promising candidate for development of novel therapeutic agents to combat fungal infections caused by C. albicans and other Candida species.


  • Open Access

    The combined action of ERG11 gene overexpression and its mutations in the development of Candida albicans resistance to triazolic antifungals

    by Yuri V. Nesvizhsky, Stanislav S. Afanasiev, Vitaly V. Zverev, Alexander D. Voropaev, Maxim S. Afanasiev, Elena A. Voropaeva, Elena V. Budanova, Ludmila M. Smirnova, Sofia A. Anisova, Yulia N. Urban, et al.

    Introduction. Modern medicine is faced with the resistance of Candida spp. to antimycotics, due to changes in the expression and structure of the ERG11 gene, the molecular target of triazoles. These mechanisms often operate simultaneously, but the interaction between them remains poorly understood. The aim of this study is to investigate the interaction between ERG11 gene overexpression and mutation in the development of triazole resistance in C. albicans. Materials and methods. Eleven C. albicans strains from the G.N. Gabrichevsky Moscow Research Institute of Epidemiology culture collection were analyzed. Each strain was characterized by its ERG11 gene expression level, the presence of ERG11 mutations, and its susceptibility to the triazoles posaconazole, voriconazole, itraconazole and fluconazole. Results. The C. albicans strains (n – number of tested strains) were categorized into four groups: Group 1 (n = 2, ERG11 overexpression only), Group 2 (n = 3, ERG11 mutations only), Group 3 (n = 4, both ERG11 overexpression and mutation) and Group 4 (n = 2, neither ERG11 overexpression nor mutation). The minimum inhibitory concentration (MIC) of Triazoles in Group 1 was 15.76-fold higher than in Group 2, 4.97-fold higher than in Group 3, and 2.51-fold lower than in Group 4 (p 0.05 for all comparisons). The MIC of triazoles in Group 2 was 3.17-fold lower than in Group 3 and 40.00-fold lower than in Group 4 (p 0.001). The MIC of triazoles in Group 3 was 12.5-fold lower than in Group 4 (p 0.001). Population-level variation in triazoles MIC was more strongly influenced by the isolated effect of ERG11 mutations (45.94%) than by the isolated effect of ERG11 overexpression (5.27-fold less). Conclusion. Triazole resistance in C. albicans is influenced by the combined actions of ERG11 overexpression and mutation. ERG11 overexpression appears to contribute more to the absolute level of resistance, while ERG11 mutations have a greater impact on the diversity of resistance levels within the C. albicans population.

  • Open Access

    Effects of the Tobacco Defensin NaD1 Against Susceptible and Resistant Strains of Candida albicans

    by Olga V. Shevchenko, Alexander D. Voropaev, Ivan V. Bogdanov, Tatiana V. Ovchinnikova, Ekaterina I. Finkina

    Today, Candida albicans is still the most common cause of both local and life-threatening systemic candidiasis. The spread of resistant fungal strains has resulted in an urgent need to search for new promising antimycotics. Here, we investigated the antifungal action of the tobacco defensin NaD1 against susceptible and resistant to azoles and echinocandins strains of C. albicans. We demonstrated that NaD1 was equally effective and fungicidal against all tested strains. The MIC and MFC values were 6.25 and 12.5 µM, respectively. We showed for the first time that NaD1 could act synergistically not only with caspofungin but also with human host defense antimicrobial peptides cathelicidin LL-37 and β-defensin-2 (HBD2) against susceptible and resistant fungal strains. Using flow cytometry, we demonstrated that NaD1 in combinations with LL-37 or HBD2 can reinforce each other by enhancing membrane disruption. Using the Caco-2 cell monolayer model, we demonstrated that NaD1 impaired the adhesion of C. albicans cells to the human epithelium. Moreover, NaD1 inhibited the formation of fungal biofilms in Sabouraud broth and less markedly in nutrient-rich RPMI-1640 medium, and enhanced the antibiofilm activity of caspofungin. Thus, we hypothesized that NaD1 might affect the development of candidiasis in vivo, including that caused by resistant fungal strains.


  • Open Access

    Spectrum and functional properties of ERG11 gene mutations in fluconazole-resistant Candida albicans strains isolated from HIV-infected patients

    by Yuri V. Nesvizhsky, Stanislav S. Afanasiev, Alexander D. Voropaev, Yulia N. Urban, Mariam E. Suleimanova, Maxim S. Afanasiev, Elena V. Budanova, Elena A. Voropaeva, Сулейманова Марьям Эмильевна, Афанасьев Максим Станиславович

    Rationale. The low efficacy of azole antimycotics in treatment of Candida infections, especially in HIV-infected patients, is often associated with overexpression of the ERG11 gene in Candida spp., which results in increased production of ergosterol the target of the above antimycotic drugs. Researchers have found ERG11 gene mutations that can modify its overexpression effects by increasing or decreasing it. However, the findings reported by different laboratories and countries are highly contradictory. The purpose of the study is to explore the spectrum and functional properties of ERG11 gene mutations in fluconazole-resistant Candida albicans strains isolated from HIV-infected patients. Materials and methods. The study was performed using 10 C. albicans strains inherently resistant to fluconazole and voriconazole and isolated from the oropharynx of HIV-infected patients; the strains were provided from the collection of the Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology. The strains were assessed by their sensitivity to antimycotic agents: anidulafungin, micafungin, caspofungin, posaconazole, voriconazole, itraconazole, fluconazole, amphotericin B, 5-flucytosine. Expression levels of the ERG11 gene were measured by quantitative PCR. ERG11 gene mutations were identified by Sanger sequencing. Results. Five mutations (E266D, G464S, I471L, D116E, and V488I) were detected in the ERG11 gene in seven C. albicans strains; six strains carried non-associated co-occurring mutations. Increased expression of the ERG11 gene was found in six C. albicans strains. The V488I mutation demonstrated a strong negative association with the increased expression of the ERG11 gene (r = 0.845; p 0.05). The minimum inhibitory concentration (MIC) in strains carrying mutations was a hundred times as low (p 0.05) as MIC in strains without mutations. In mutation carriers, posaconazole and itraconazole MICs were on average 16.5 times as low as MICs of voriconazole and fluconazole (p 0.001). The presence of mutations in the ERG11 gene had almost no effect on MICs of the tested antimycotics of the echinocandin, polyene, and pyrimidine groups. Conclusion. Multiple mutations were detected in the ERG11 gene in most of the C. albicans strains isolated from HIV-infected patients and resistant to fluconazole and voriconazole. Except for the V488I mutation, the detected mutations were not associated with the overexpression of the ERG11 gene and decreased the effects of overexpression of the ERG11 gene by up to 100 times, though they did not eliminate the inherent resistance to triazole antimycotics.


  • Open Access

    Immunomodulatory Effects of the Pea Defensin Psd1 in the Caco-2/Immune Cells Co-Culture upon Candida albicans Infection

    by Ivan V. Bogdanov, Serafima I. Fateeva, Alexander D. Voropaev, Tatiana V. Ovchinnikova, Ekaterina I. Finkina

    Candidiasis is one of the most common fungal diseases that can pose a threat to life in immunodeficient individuals, particularly in its disseminated form. Not only fungal invasion but also fatal infection-related inflammation are common causes of systemic candidiasis. In this study, we investigated in vitro immunomodulatory properties of the antifungal pea defensin Psd1 upon Candida albicans infection. Using the real-time PCR, we showed that Psd1 inhibited the antimicrobial peptide HBD-2 and pro-inflammatory cytokines IL-1 and IL-8 downregulation at mRNA level in epithelium cells caused by C. albicans infection. By using the Caco-2/immune cells co-culture upon C. albicans infection and the multiplex xMAP assay, we demonstrated that this pathogenic fungus induced a pronounced host defense response; however, the cytokine responses were different in the presence of dendritic cells or monocytes. We revealed that Psd1 at a low concentration (2 µM) had a pronounced immunomodulatory effect on the Caco-2/immune cells co-culture upon fungal infection. Thus, we hypothesized that the pea defensin Psd1 might be an effective agent in the treatment of candidiasis not only due to its antifungal activity, but also owing to its ability to modulate a protective immune response upon infection.


  • Open Access

    The association between Candida albicans sensitivity to antimycotic drugs and the architecture of their microbial community in the oropharynx of HIV infected patients

    by Yuri V. Nesvizhsky, Alexander D. Voropaev, Stanislav S. Afanasiev, Elena V. Volchkova, Maxim S. Afanasiev, Elena A. Voropaeva, Mariam E. Suleimanova, Elena V. Budanova, Yulia N. Urban, Афанасьев Максим Станиславович, et al.

    Relevance. Candida infection remains relevant due to the wide spread of antimycotic-resistant strains of Candida fungi, especially among immunocompromised individuals. It was previously discovered that the Candida spp. microbial community in the biotope of the oropharynx of HIV infected patients is characterized by a certain architecture: they can be present in this biotope in the form of a monoculture or as association of co-isolates. It has been suggested that the architecture of the Candida microbial community may influence their resistance to antimycotic drugs. Purpose a comparative study of the association between the architecture of the C. albicans microbial community in the oropharynx of HIV infected patients with oropharyngeal candidiasis and their sensitivity to antimycotic drugs. Materials and methods. A microbiological study of 52 isolates of Candida fungi (C. albicans, C. glabrata, C. tropicalis and C. krusei) from the oropharynx of 31 HIV infected patients with clinical manifestations of oropharyngeal candidiasis aged 20 to 69 years with almost equal gender distribution was carried out. In the form of monocultures, 18 isolates were isolated, while 34 were identified as co-isolates, which formed 16 homogeneous communities that included strains of the same species, and 18 heterogeneous ones that consisted of fungi of various species. Results. It was found that heterogeneous communities of C. albicans were markedly distinguished by sensitivity to antimycotic drugs, in particular, by low sensitivity to imidazoles. Homogeneous communities practically did not differ from monocultural ones. The general properties of the C. non-albicans population were largely similar to those of C. albicans, but were characterized by lower heterogeneity in response to antimycotic drugs. Conclusion. The architecture of the community of C. albicans isolated from the oropharynx of HIV infected patients with clinical manifestations of oropharyngeal candidiasis affects their sensitivity to antimycotic drugs. When selecting effective antimycotic therapy for such patients, it is necessary to take into account the structure of the Candida spp. community in the oropharynx.


  • Open Access

    CDR1, CDR2, MDR1 and ERG11 expression in azole resistant Сandida albicans isolated from HIV-infected patients in city of Moscow

    by A. D. Voropaev, D. A. Yekaterinchev, Y. N. Urban, V. V. Zverev, Yu. V. Nesvizhsky, E. A. Voropaeva, E. I. Likhanskaya, M. S. Afanasiev, S. S. Afanasiev

    Candida fungi are common opportunistic microorganisms capable of causing infections of various localization, as well as life-threatening conditions in immunocompromised patients, such as HIV-infected individuals, oncology patients, subjects undergoing HSCT, which number has been steadily increasing in recent years. In addition, resistance to anti-fungal drugs has been spreading as well. Naturally sensitive to azoles, C. albicans possess a variety of mechanisms of acquired resistance, including efflux transporters and target protein-encoding gene amplification. This study was conducted to assess a prevalence of such mechanisms in the isolates sample obtained from HIV-infected patients in the Moscow region of the Russian Federation, characterize a relationship between these mechanisms and patterns of developing drug resistance. 18 strains of C. albicans resistant to fluconazole and voriconazole were isolated from HIV-infected patients with recurrent oropharyngeal candidiasis in the Moscow region. The expression levels of the ERG11, MDR1, CDR1, CDR2 genes involved in the formation of acquired azole resistance were measured using quantitative PCR, the 2CT method with ACT and PMA genes as control genes and reference values of sensitive isolates. Expression levels exceeding the average values of sensitive isolates by more than 3 standard deviations were considered significantly elevated. In most of the isolates, elevated levels of CDR1 and CDR2 gene expression were found: 89% and 78%, respectively. The expression level of the MDR1 gene was increased only in 28% of cases. ERG11 expression levels were significantly elevated in 78% of the isolates. Expression levels of all resistance genes studied were significantly increased in 4 strains. In this sample of C. albicans isolates, acquired resistance is mainly associated with efflux vectors encoded by the CDR1 and CDR2 genes. Also, in most isolates, an increased expression level for the azole target protein gene ERG11 was detected. The expression level of the efflux transporter gene MDR1 was increased in the smallest number of samples. It is also impossible to exclude a potential role of other mechanisms in developing acquired resistance, such as mutations in the ERG11 gene. It can be assumed that the identified mechanisms of resistance result from long-term, widespread, and sometimes uncontrolled use of azoles, including those in treatment and prevention of candidiasis in HIV-infected patients.


  • Open Access

    Antifungal Activity, Structural Stability, and Immunomodulatory Effects on Human Immune Cells of Defensin from the Lentil Lens culinaris

    by Ekaterina I. Finkina, Ivan V. Bogdanov, Anastasia A. Ignatova, Marina D. Kanushkina, Ekaterina A. Egorova, Alexander D. Voropaev, Elena A. Stukacheva, Tatiana V. Ovchinnikova

    An increase in the frequency of mycoses and spreading of multidrug-resistant fungal pathogens necessitates the search for new antifungal agents. Earlier, we isolated the novel defensin from lentil Lensculinaris seeds, designated as Lc-def, which inhibited the growth of phytopathogenic fungi. Here, we studied an antifungal activity of Lc-def against human pathogenic Candida species, structural stability of the defensin, and its immunomodulatory effects that may help to prevent fungal infection. We showed that Lc-def caused 50% growth inhibition of clinical isolates of Candida albicans, C. krusei, and C. glabrata at concentrations of 25–50 μM, but was not toxic to different human cells. The lentil defensin was resistant to proteolysis by C. albicans and was not cleaved during simulated gastroduodenal digestion. By using the multiplex xMAP assay, we showed for the first time for plant defensins that Lc-def increased the production of such essential for immunity to candidiasis pro-inflammatory cytokines as IL-12 and IL-17 at the concentration of 2 μM. Thus, we hypothesized that the lentil Lc-def and plant defensins in general may be effective in suppressing of mucocutaneous candidiasis due to their antifungal activity, high structural stability, and ability to activate a protective immune response.